EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer

Romain Chautard, Morgane Caulet, Olivier Bouché, Christophe Borg, Sylvain Manfredi, Olivier Capitain, Jean-Philippe Spano, William Raoul, Maxime Guéguinou, Olivier Herault, Aurélie Ferru, Cédric Pobel und 2 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2024.07.022 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Romain Chautard und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Régional Universitaire de Tours, Université François Rabelais, Tours…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment. We aimed to evaluate the prognostic yield of serum mid-infrared spectroscopy (MIRS) on patients receiving first-line bevacizumab-based chemotherapy for mCRC. METHODS: We conducted an ancillary analysis from a multicentre prospective study (NCT00489697). All baseline serums were screened by attenuated total reflection method. Principal component analysis and unsupervised k-mean partitioning methods were performed blinded to all patients' data. Endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: From the 108 included patients, MIRS discriminated two prognostic groups. First group patients had significantly lower body mass index (p = 0.026) and albumin levels (p < 0.001), and higher levels of angiogenic markers, lactate dehydrogenase and carcinoembryonic antigen (p < 0.001). In univariate analysis, their OS and PFS were shorter with respective medians: 17.6 vs 27.9 months (p = 0.02) and 8.7 vs 11.3 months (p = 0.03). In multivariate analysis, PFS was significantly shorter (HR = 1.74, p = 0.025) with a similar trend for OS (HR = 1.69, p = 0.061). CONCLUSION: By metabolomic fingerprinting, MIRS proves to be a promising prognostic tool for patients receiving first-line bevacizumab-based chemotherapy for mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedProspective StudiesPrognosisBiomarkers, TumorAdultProgression-Free Survival

Stichwörter der Autor:innen

BevacizumabBiomarkerMetastatic colorectal cancerMid-infrared spectroscopy

Substanzen

BevacizumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Régional Universitaire de Tours, Université François Rabelais, Tours, France; Université de Tours, Inserm, UMR 1069, Nutrition Croissance…
  • Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Régional Universitaire de Tours, Université François Rabelais, Tours, France.
  • Department of Digestive Oncology, Hôpital Robert Debré, CHU de Reims, Avenue Général Koenig, 51092, Reims, France.
  • Department of Medical Oncology, Hôpital Jean Minjoz, CHRU de Besançon, 3 Boulevard Alexandre Fleming, 25000, Besançon, France.
  • Department of Gastroenterology, CHU Dijon, University of Bourgogne-Franche Comté, INSERM U1231, Dijon, France.
  • Department of Medical Oncology, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.

Zitieren

APA

Chautard, R., Caulet, M., Bouché, O., Borg, C., Manfredi, S., Capitain, O., Spano, J. P., Raoul, W., Guéguinou, M., Herault, O., Ferru, A., Pobel, C., Sire, O., & Lecomte, T. (2025). Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.07.022

Vancouver

Chautard R, Caulet M, Bouché O, Borg C, Manfredi S, Capitain O, et al. Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.07.022

BibTeX
@article{Chautard2025,
  author = {Chautard, Romain and Caulet, Morgane and Bouché, Olivier and Borg, Christophe and Manfredi, Sylvain and Capitain, Olivier and Spano, Jean-Philippe and Raoul, William and Guéguinou, Maxime and Herault, Olivier and Ferru, Aurélie and Pobel, Cédric and Sire, Olivier and Lecomte, Thierry},
  title = {Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2024.07.022}
}
Kostenlos starten →